Bauman JN, Doran AC, King-Ahmad A, Sharma R, Walker GS, Lin J et al (2022) The pharmacokinetics, metabolism, and clearance mechanisms of abrocitinib, a selective Janus kinase inhibitor, in humans. Drug Metab Dispos 50:1106–1118

Article  CAS  PubMed  Google Scholar 

Beck LA, Thaçi D, Deleuran M, Blauvelt A, Bissonnette R, de Bruin-Weller M et al (2020) Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 21:567–577

Article  PubMed  PubMed Central  Google Scholar 

Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I et al (2019) Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol 144:1274–1289

Article  CAS  PubMed  Google Scholar 

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287–2303

Article  CAS  PubMed  Google Scholar 

Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S et al (2022) Long-term 2 year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol 87:815–824

Article  CAS  PubMed  Google Scholar 

Chang EH, Carnevale D, Chavan SS (2023) Editorial: understanding and targeting neuro-immune interactions within disease and inflammation. Front Immunol 18(14):1201669. https://doi.org/10.3389/fimmu.2023.1201669

Article  CAS  Google Scholar 

Chen Q, Cui L, Hu Y, Chen Z, Gao Y, Shi Y (2023) Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: a systematic review and meta-analysis. Heliyon 9(11):e22014. https://doi.org/10.1016/j.heliyon.2023.e22014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colletti A, Pellizzato M, Cicero AF (2023) The possible role of probiotic supplementation in inflammation: a narrative review. Microorganisms 11(9):2160. https://doi.org/10.3390/microorganisms11092160

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cork MJ, Thaçi D, Eichenfield LF, Arkwright PD, Sun X, Chen Z, Akinlade B et al (2021) Dupilumab provides favourable long-term safety and efficacy in children aged ≥6 to <12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 184:857–870

Article  CAS  PubMed  Google Scholar 

Czarnowicki T, He H, Krueger JG, Guttman-Yassky E (2019) Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol 143:1–11

Article  PubMed  Google Scholar 

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q et al (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 178:1083–1101

Article  PubMed  Google Scholar 

Drakos A, Torres T, Vender R (2024) Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. Pharmaceutics 16(1):111. https://doi.org/10.3390/pharmaceutics16010111

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Shu-Ching Chang T, Koguchi Y et al (2021) Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. Nat Commun 12:1047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrara F, Vitiello A (2021) Scientific Hypothesis for treatment of COVID-19’s lung lesions by adjusting ACE/ACE2 Imbalance. Cardiovasc Toxicol 21(6):498–503. https://doi.org/10.1007/s12012-021-09649-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furue K, Ito T, Tsuji G, Ulzii D, Vu YH, Kido-Nakahara M et al (2019) The IL-13-OVOL1-FLG axis in atopic dermatitis. Immunology 158:281–286

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfeld C et al (2019) Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol 155:1371–1379

Article  PubMed  PubMed Central  Google Scholar 

Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S et al (2022) Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol 186:440–452

Article  CAS  PubMed  Google Scholar 

Guttman-Yassky E, Pavel AB, Zhou L, Estrada YD, Zhang N, Xu H et al (2019a) GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol 144:482-93e7

Article  CAS  PubMed  Google Scholar 

Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R et al (2019b) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80:913-21e9

Article  CAS  PubMed  Google Scholar 

Guttman-Yassky E, Blauvelt A, Eichenfeld LF, Paller AS, Armstrong AW, Drew J et al (2020a) Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b Randomized Clinical Trial. JAMA Dermatol 156:411–420

Article  PubMed  PubMed Central  Google Scholar 

Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC, Paap KA, Reich A et al (2020b) Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020(145):877–884

Article  Google Scholar 

Harb H, Chatila TA (2019) Mechanisms of dupilumab. Clin Exp Allergy 50:5–14

Article  PubMed  PubMed Central  Google Scholar 

Kwon S (2022) Molecular dissection of Janus kinases as drug targets for inflammatory diseases. Front Immunol 8(13):1075192. https://doi.org/10.3389/fimmu.2022.1075192

Article  CAS  Google Scholar 

Licata G, Gambardella A, Tancredi V, Calabrese G, De Rosa A, Alfano R et al (2022) Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol 36:e150–e152

Article  CAS  PubMed  Google Scholar 

Mazzoleni L, Borsino C, Zovi A (2022) Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison. Eur J Hosp Pharm. https://doi.org/10.1136/ejhpharm-2021-003202

Article  PubMed  PubMed Central  Google Scholar 

Mogul A, Corsi K, McAuliffe L (2019) Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 53:947–953

Article  CAS  PubMed  Google Scholar 

Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S et al (2016) The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo- controlled study. Br J Dermatol 174:296–304

Article  CAS  PubMed  Google Scholar 

Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC (2020) New and emerging systemic treatments for atopic dermatitis. Drugs 80:1041–1052

Article  PubMed  PubMed Central  Google Scholar 

Paller AS, Wollenberg A, Siegfried E, Thaçi D, Cork MJ, Arkwright PD et al (2021) Laboratory Safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis: results from a phase iii clinical trial. Paediatr Drugs 23:515–527

Article  PubMed  PubMed Central  Google Scholar 

Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Freidman M et al (2018) In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2:23

Article  PubMed  PubMed Central  Google Scholar 

Patruno C, Fabbrocini G, Longo G, Argenziano G, Ferrucci SM, Stingeni L et al (2021a) Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. Am J Clin Dermatol 22:581–586

Article  PubMed  Google Scholar 

Patruno C, Napolitano M, Argenziano G, Peris K, Ortoncelli M, Girolomoni G et al (2021b) DADE-Dupilumab for Atopic Dermatitis of the Elderly study group. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol 35:958–964

Article  CAS  PubMed  Google Scholar 

Pfizer announces positive top-line results from phase 3 study of investigational oral Jak1 candidate, abrocitinib (Pf-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (2019) Disponibile on line su: ultimo access [10 november 2022]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis

Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K et al (2021) Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397:2169–2181

Article  CAS  PubMed